Startseite Kongressberichte 2021 63rd ASH Annual Meeting and Exposition In-Person/Virtual Myeloprolifertive Syndromes Risk Stratification and Prognostication Clinically Relevant Abstract

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Risk Stratification and Prognostication

235 ASH denotes this abstract as clinically relevant
Excess Mortality in Young Patients with Myeloproliferative Neoplasms

Khalid Abu-Zeinah, Khalil Saadeh, Richard T. Silver, et al.

An unacceptably high excess mortality has been observed in MPN patients under the age of 60. It is higher than in patients over 60 years of age.

 

236 ASH denotes this abstract as clinically relevant
The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, et al.

The IPSS score can be useful in conjunction with the JAK2 mutation in addition to assessing the risk of survival. It helps to identify patients at vascular risk and suggest suitable antithrombotic prophylaxis.

 

237 ASH denotes this abstract as clinically relevant
A JAK2V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis

Giuseppe Gaetano Loscocco, Paola Guglielmelli, Carmela Mannarelli, et al.

AT and VT are associated with unique risk factors in patients with PV. This is illustrated by data with JAK2VF VAF as a strong independent predictor of future venous thrombosis in PV associated with the previous history of venous events.

 

238 ASH denotes this abstract as clinically relevant
A Globally Applicable “Triple AAA” Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count

Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, et al.

Elevated ANC and decreased ALC are age-independent risk factors for survival in ET. The present study has identified this and thus enables the development of a globally applicable, easy-to-use “triple-A” risk model based on age, ANC, and ALC. Decreased ALC also predicted fibrotic and leukemic progression. The observations of the study authors suggest a potential value for immune profiling as an additional prognostic tool in MPN.

 

239 ASH denotes this abstract as clinically relevant
A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Aaron T. Gerds, Ruben A. Mesa, John M. Burke, et al.

Increased HCT levels (> 45%) as well as leukocytes (> 11 × 109 / l) and PLT numbers (> 400 × 109 / l)) were each associated with an increased risk of TE. For more info see abstract.

 

240 ASH denotes this abstract as clinically relevant
European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database

Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, et al.

For more info see abstract.